Holen Sie sich die Stockscreener-App
752.79
2.38%
-18.46
Schlusskurs vom Vortag:
$771.25
Offen:
$765.15
24-Stunden-Volumen:
201.87K
Relative Volume:
0.21
Marktkapitalisierung:
$79.12B
Einnahmen:
$14.25B
Nettoeinkommen (Verlust:
$4.58B
KGV:
18.02
EPS:
41.7701
Netto-Cashflow:
$3.88B
1W Leistung:
+0.48%
1M Leistung:
-4.09%
6M Leistung:
+34.77%
1J Leistung:
+9.70%
1-Tages-Spanne:
$752.00
$766.99
1-Wochen-Bereich:
$747.30
$776.25
52-Wochen-Spanne:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Firmenname
Regeneron Pharmaceuticals Inc
Sektor
Branche
Telefon
(914) 847-7000
Adresse
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Vergleichen Sie REGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
752.78 | 81.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.97 | 120.31B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ARGX
Argen X Se Adr
|
847.08 | 53.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
351.06 | 46.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
347.35 | 37.20B | 4.98B | 69.59M | 525.67M | 0.5197 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Hochstufung | BofA Securities | Underperform → Buy |
| 2025-12-03 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Eingeleitet | HSBC Securities | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-14 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Herabstufung | Argus | Buy → Hold |
| 2025-05-30 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-09-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Eingeleitet | Bernstein | Outperform |
| 2024-01-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Bestätigt | Oppenheimer | Perform |
| 2023-06-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-23 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2023-01-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-09-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-12-07 | Fortgesetzt | Cowen | Market Perform |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2021-11-05 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-01-25 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-10-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Hochstufung | SunTrust | Hold → Buy |
| 2020-05-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-17 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Eingeleitet | The Benchmark Company | Hold |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-11 | Hochstufung | Argus | Hold → Buy |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-16 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Hold |
| 2019-11-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
Alle ansehen
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings? - TradingView
Federated Hermes Inc. Has $132.81 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Cambiar Investors LLC Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Cullen Frost Bankers Inc. - MarketBeat
Eylea HD Approval And STEM Focus Shape Regeneron’s Growth Outlook - simplywall.st
Atopic Dermatitis Market to Reach USD 12.97 Billion by 2034, Growing at 7.75% CAGR - GlobeNewswire Inc.
Regeneron (REGN) Posted Solid Quarterly Results, Eyes 2026 Pipeline Catalysts - Insider Monkey
Analysts Are Bullish on These Healthcare Stocks: Guardant Health (GH), Regeneron (REGN) - The Globe and Mail
Intellia rises as FDA lifts clinical hold on Regeneron-partnered gene editing drug - Seeking Alpha
Lbp Am Sa Grows Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Compass Wealth Management LLC Buys Shares of 3,634 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
General American Investors Co. Inc. Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Sovran Advisors LLC Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
Regeneron Pharmaceuticals (REGN) Valuation Check After Eylea HD Approval And Ongoing Dupixent Momentum - simplywall.st
Y Intercept Hong Kong Ltd Sells 24,556 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Stoneridge Investment Partners LLC Buys Shares of 2,360 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Resona Asset Management Co. Ltd. Sells 5,371 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Teacher Retirement System of Texas Sells 2,558 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
What Regeneron Pharmaceuticals (REGN)'s Eylea HD Progress and STEM Investment Push Means For Shareholders - simplywall.st
Oxbow Advisors LLC Takes $2.95 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Wealth Enhancement Advisory Services LLC - MarketBeat
Regeneron: Q4 Earnings PreviewWhy I'm Expecting A Beat And Strong 2026 (NASDAQ:REGN) - Seeking Alpha
Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Finviz
Big Pharma shops Chinese biotechs to stock GLP-1 pipelines - Pharma Voice
The Truth About Regeneron Pharmaceuticals: Why Wall Street Can’t Stop Watching REGN - AD HOC NEWS
How Regeneron’s Broader Biologics Pipeline And Capital Return Focus At Regeneron Pharmaceuticals (REGN) Has Changed Its Investment Story - Yahoo Finance
Is Regeneron Pharmaceuticals (REGN) Still Attractive After Recent Share Price Weakness? - simplywall.st
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Regeneron Pharmaceuticals (REGN) Projected to Post Quarterly Earnings on Friday - MarketBeat
Bi Specific Antibodies Therapy Market Is Booming Worldwide | AbbVie • Regeneron Pharmaceuticals • Pfizer - openPR.com
2 Healthcare Stocks Poised for a Comeback in 2026 - Finviz
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $875.00 at Evercore ISI - MarketBeat
REGN: Evercore ISI Group Raises Price Target to $875, Maintains Outperform Rating | REGN Stock News - GuruFocus
Analysts Crow About Potential Of Corvus Pill To Beat Dupixent - Citeline News & Insights
Universal Beteiligungs und Servicegesellschaft mbH Increases Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Faces Neurology Leadership Shift As Investors Weigh Pipeline Execution - simplywall.st
Ocular Therapeutix Appoints David W. Robinson as Global Chief Commercial Officer - citybiz
2 Westchester County Teens Among 40 Regeneron Science Talent Search 2026 Finalists - Patch
40 teen scientists vie for $1.8M at Regeneron talent search - Stock Titan
58,906 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Rakuten Investment Management Inc. - MarketBeat
Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer - manilatimes.net
Seizert Capital Partners LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
(REGN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Should You Be Excited for Regeneron (REGN)? - Insider Monkey
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Momentum - Yahoo Finance
Allstate Corp Makes New $2.12 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Expansion wave in Saratoga County, New York: Regeneron, GlobalFoundries, Soleno, LISSMAC and more - The Business Journals
Third retinal indication for Eylea 8mg approved in Europe - The Pharma Letter
Sanofi, Regeneron Can't Patent Asthma Prevention Tool - Law360
Neutralizing Antibody Market is Going to Boom, Highlighting - openPR.com
Finanzdaten der Regeneron Pharmaceuticals Inc-Aktie (REGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.04%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):